ArticleEuropean journal of medical research2023
Exploring the clinical application value of peripheral blood T lymphocyte subset in patients with asymptomatic omicron infection.
Article in European journal of medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SARS-CoV-2 peptide fragments selectively dysregulate specific immune cell populations via Gaussian curvature targeting.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the clinical significance and value of peripheral blood T lymphocyte subset in patients with asymptomatic novel coronavirus variant strains infection (OMICRON).
methodsA retrospective analysis of 281 patients with asymptomatic OMICRON infection who were admitted and isolated to the Fuyang Second People's Hospital from March to April 2022 was conducted. With 32 normal people as the control group, T lymphocytes of the two groups (CD3 + T, CD3 + CD4 + T, CD3 + CD8 + T) were analyzed and the differences between the two groups were analyzed. CD4 + T lymphocytes between patients with asymptomatic OMICRON infection and patients with mild COVID-19 infection in 2020 were analyzed and compared. Based on CD3 CD4 + T lymphocyte changes, lymphocyte reference range: CD3 CD4 + T lymphocyte count 404-1612/μL. Lower than 404 × 106/μL was defined as lymphocytopenia, patients were divided into the reduced group (138) and the normal group (143). The CT value of novel coronavirus nucleic acid (ORF1ab gene, N gene) and the time of viral shedding were compared between the two groups.
resultsDifferences in number of CD3 + T cells, CD3 + CD4 + T cells, and CD3 + CD8 + T cells were significant between both groups (P < 0.05), which were significantly higher in the normal population than in the patients with asymptomatic OMICRON infection. There was no significant difference in CD4 + T lymphocytes between patients with asymptomatic OMICRON infection and patients with mild COVID-19 infection in 2020 (P < 0.05). The novel coronavirus nucleic CT value was significantly lower in the CD3CD4 + T lymphocyte-reduced group than in the CD3CD4 + T lymphocyte-normal group (P < 0.05). Moreover, the time of viral shedding was significantly longer in the reduced group compared with the normal group (P < 0.05).
conclusionThe changing characteristics of the peripheral blood T lymphocyte subset count in patients with asymptomatic OMICRON infections can provide an important basis for the diagnosis and outcome of the asymptomatic OMICRON infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.